Form 4: Tempus AI Boosts Stake in Personalis

Tempus AI, a significant shareholder and director, increased its beneficial ownership in Personalis, Inc. by acquiring over 320,000 common shares across multiple transactions in late 2025.

Summary

• Tempus AI, Inc., identified as both a Director and a 10% Owner of Personalis, Inc. (PSNL), acquired a total of 320,267 shares of Personalis Common Stock.
• These acquisitions were conducted through multiple open market purchases between November 18, 2025, and December 22, 2025.
• The weighted average purchase prices for these shares ranged from $7.67 to $11.00 per share.
• Following these reported transactions, Tempus AI, Inc. beneficially owns a total of 13,039,067 shares of Personalis Common Stock.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as substantial and consistent insider buying by a major shareholder and director typically reflects high confidence in the company's future performance and valuation.

Positives

• Significant insider buying by Tempus AI, Inc., a major shareholder and director, signals strong confidence in Personalis, Inc.'s future prospects and valuation.
• The consistent accumulation of shares across multiple dates and varying price points suggests a strategic, long-term investment perspective rather than short-term speculation.
• The acquisition of 320,267 additional shares represents a substantial increase in beneficial ownership, further aligning Tempus AI's interests with those of other shareholders.

Negatives

• No negative information is present in this Form 4 filing, as it exclusively reports insider acquisitions.

Risks

• This Form 4 filing primarily reports insider trading activity and does not detail specific operational, financial, or market risks pertinent to Personalis, Inc.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding Personalis, Inc.'s future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider buying, especially by a significant institutional shareholder and director like Tempus AI, Inc., often signals strong internal conviction in the company's valuation and future prospects within the competitive genomics and healthcare technology sector. This activity could be interpreted as a positive indicator, particularly in an industry characterized by rapid innovation and high capital requirements.

Comparison to Industry Standards

• StockSavvy.ai observes that substantial insider purchases, such as those by Tempus AI in Personalis, Inc., are generally viewed favorably by the market. While direct comparisons to specific companies or projects are not provided in this filing, such sustained buying activity by a strategic investor often precedes positive developments or reflects a belief that the stock is undervalued relative to its peers in the biotechnology and precision medicine space.
• For instance, similar patterns of significant insider accumulation have been seen in companies like Guardant Health (GH) or Invitae (NVTA) during periods of perceived undervaluation or strategic shifts, though the specific context and scale may vary.

Management Changes

Corporate Governance

Legal Proceedings

• This filing does not report any litigation or regulatory matters.

Related Party Transactions

• Tempus AI, Inc., as a 10% owner and director of Personalis, Inc., engaged in multiple open market purchases of Personalis common stock. These transactions are considered related party dealings due to Tempus AI's significant influence and board representation.

Stakeholder Impact

• Shareholders: The increased stake by a major institutional investor and director could instill greater confidence among existing shareholders and potentially attract new investors, signaling strong internal belief in the company's value.
• Employees: While not directly impacted, a stronger share price or positive market sentiment resulting from insider buying could indirectly boost employee morale, especially for those with equity compensation.
• Customers/Suppliers/Creditors: No direct impact is expected on these stakeholders from this specific filing.

Next Steps

• The filing does not explicitly mention future actions or milestones for Personalis, Inc. beyond the reporting of past transactions.

Key Dates

Recommendation

The consistent and substantial insider buying by Tempus AI, Inc., a significant shareholder and director, signals strong conviction in Personalis, Inc.'s future prospects and potential undervaluation. Such informed buying activity by a major stakeholder is a powerful indicator for seasoned investors, suggesting a favorable outlook for the stock.

Keywords

Personalis, PSNL, Tempus AI, Insider Buying, Form 4, Share Acquisition, Biotechnology, Genomics, Healthcare Technology, Director Ownership, 10% Owner